On October 2, 2018 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, reported publication of important research in the peer-reviewed journal Cancer Immunology Research (Press release, Oncolytics Biotech, OCT 2, 2018, View Source [SID1234530640]). The research showed that pelareorep, a systemically delivered oncolytic reovirus, can destroy tumor cells via a monocyte-mediated process even after the virions have been exposed to antibodies designed to neutralize the reovirus.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"For some time there have been two schools of thought regarding oncolytic viruses: those that believe intratumoral delivery is necessary for treatment due to potential neutralization of the virus in the bloodstream and those that believe intravenous delivery is also an efficacious means of treatment with a virus," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. "This key publication validates the systemic delivery of oncolytic viruses by proving that oncolytic viruses delivered intravenously can be effective even in the presence of neutralizing antibodies. It sends a message to everyone in the oncology community that systemic delivery of this drug class is not only viable, but may increase its effectiveness in the presence of neutralizing antibodies."
The study was conducted by Dr. Elizabeth Ilett and Dr. Rob Berkeley from the University of Leeds and Professor Alan Melcher from The Institute of Cancer Research, London. Oncolytics Biotech donated pelareorep for research.
In the study, researchers treated pelareorep with neutralizing antibodies derived from patients undergoing virus therapy and added the antibody-coated virions to melanoma cells, which resulted in no killing of melanoma cells. However, addition of monocytes to the culture led to reactivation of the neutralized virus particles, allowing them to effectively target and destroy the melanoma cells. Three different viruses that are currently being evaluated in clinical trials were tested in the study, with neutralized forms of two of the three viruses being reactivated by monocytes, a finding with immediate clinical significance.
"This discovery suggests that cancer treatments using systemic virus therapy could be significantly expanded in the future, as we previously, but erroneously, believed that follow-up doses were useless once the body had produced antibodies against the virus," said Dr. Ilett.
About Pelareorep
Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers.